Molecular Pathology Laboratory Network, Inc. (MPLN) acquires the Illumina MiSeqDx™ next generation sequencing system to expand its portfolio of molecular testing and clinical research services to support growing demand in personalized medicine.
November 26 – Maryville, Tennessee – Molecular Pathology Laboratory Network, Inc. (MPLN) announced today that it has acquired the Illumina MiSeqDx™, currently the only next generation sequencing system cleared by the US Food and Drug Administration (FDA) for targeted sequencing of human genomic DNA. MPLN will be the first laboratory in the country to own the FDA cleared version of this revolutionary technology, and will leverage the system for the expansion of testing across all of its clinical laboratories including its clinical trials group Geneuity Clinical Research Services.
This exciting new technology is capable of screening numerous gene targets simultaneously at a fraction of today’s costs and does so with phenomenally high throughput. MPLN, a molecular reference laboratory specializing in Oncology, Women’s Health, and clinical research services, will utilize the Illumina MiSeqDx™ to offer physicians greater access to clinically actionable data at the gene level, and ultimately the facilitation of better patient outcomes.
“We are proud to soon host this revolutionary technology in-house and be the first lab in the country to offer such comprehensive DNA sequencing analysis,” said Dr. Roger Hubbard, MPLN Chief Executive Officer. “The Illumina MiSeqDx™ truly enhances our ability to offer the most comprehensive testing services personalized to the level of each person’s unique genetic make-up.”
No comments yet. Be the first to leave a comment below.